Skye Bioscience (SKYE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
28 May, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Pacific Time on May 26, 2026, with board nominees and independent auditor present.
Inspector of Election appointed and oath filed; meeting held per notice and proxy statement.
Proof of mailing of proxy materials and notice to stockholders certified and filed.
Shareholder proposals
Four proposals presented: election of six directors, ratification of auditor, amendment to increase authorized shares, and advisory vote on executive compensation.
Overview of voting outcomes
Quorum established with 66.98% of shares represented.
All six director nominees elected for one-year terms expiring at the 2027 meeting.
Auditor ratified for fiscal year ending December 31, 2026.
Amendment to increase authorized shares from 100 million to 300 million approved.
Advisory approval of executive compensation passed.
Final vote results to be reported in a Form 8-K within four business days.
Latest events from Skye Bioscience
- Skye and Redx to merge as Fibrx Therapeutics, raising $125M and advancing fibrosis therapies.SKYE
Proxy filing - Merger forms Nasdaq-listed fibrosis company, funded by $125M, advancing RXC008 for Crohn's.SKYE
M&A announcement - Terminated nimacimab R&D, pursuing Redx Pharma acquisition, facing liquidity and Nasdaq risks.SKYE
Q2 2026 - Nimacimab plus semaglutide achieved 22.3% weight loss at 52 weeks with strong safety and scalability.SKYE
Corporate presentation - Q1 net loss reached $12.5M as nimacimab combo therapy advanced amid funding risks.SKYE
Q1 2026 - Nimacimab plus semaglutide delivers durable, additive weight loss; cash runway through Q4 2026.SKYE
Q4 2025 - Nimacimab plus semaglutide achieved superior weight loss and safety versus semaglutide alone.SKYE
Study Update - Q3 net loss narrowed to $3.9M as Phase 2 nimacimab obesity trial advanced and cash reserves grew.SKYE
Q3 2024 - Nimacimab Phase 2a trial enrollment exceeded targets, accelerating data and strengthening cash runway.SKYE
Q4 2024